- Home
- TWFG vs CELC Comparison
TWFG vs CELC Comparison
Compare TWFG & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWFG
- CELC
- Stock Information
- Founded
- TWFG 2001
- CELC 2011
- Country
- TWFG United States
- CELC United States
- Employees
- TWFG N/A
- CELC N/A
- Industry
- TWFG
- CELC Medical Specialities
- Sector
- TWFG
- CELC Health Care
- Exchange
- TWFG NYSE
- CELC Nasdaq
- Market Cap
- TWFG 437.4M
- CELC 391.0M
- IPO Year
- TWFG 2024
- CELC 2017
- Fundamental
- Price
- TWFG $31.36
- CELC $9.36
- Analyst Decision
- TWFG Buy
- CELC Strong Buy
- Analyst Count
- TWFG 8
- CELC 6
- Target Price
- TWFG $33.14
- CELC $30.17
- AVG Volume (30 Days)
- TWFG 91.3K
- CELC 288.5K
- Earning Date
- TWFG 05-15-2025
- CELC 05-14-2025
- Dividend Yield
- TWFG N/A
- CELC N/A
- EPS Growth
- TWFG N/A
- CELC N/A
- EPS
- TWFG 0.19
- CELC N/A
- Revenue
- TWFG $203,760,000.00
- CELC N/A
- Revenue This Year
- TWFG $22.49
- CELC N/A
- Revenue Next Year
- TWFG $18.64
- CELC N/A
- P/E Ratio
- TWFG $164.23
- CELC N/A
- Revenue Growth
- TWFG 18.44
- CELC N/A
- 52 Week Low
- TWFG $21.31
- CELC $8.50
- 52 Week High
- TWFG $36.50
- CELC $20.89
- Technical
- Relative Strength Index (RSI)
- TWFG N/A
- CELC 36.84
- Support Level
- TWFG N/A
- CELC $8.50
- Resistance Level
- TWFG N/A
- CELC $10.91
- Average True Range (ATR)
- TWFG 0.00
- CELC 0.72
- MACD
- TWFG 0.00
- CELC -0.05
- Stochastic Oscillator
- TWFG 0.00
- CELC 32.21
About TWFG TWFG INC
TWFG Inc is a independent distribution platform for personal and commercial insurance in the United States. It offers all lines of insurance, multiple distribution contract options, M&A services, proprietary virtual assistants, proprietary technology, proprietary premium financing, unlimited continuing education, recognition programs, co-op funding, marketing support and overall lower costs to operate.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.